Xlrn stock price target

Acceleron Pharma Inc (NASDAQ:XLRN) was up 8% during mid-day trading on Monday after Oppenheimer raised their price target on the stock from $108.00 to $112.00. Oppenheimer currently has an outperform rating on the stock. Acceleron Pharma traded as high as $88.33 and last traded at $87.21, approximately 560,939 shares changed hands during mid-day trading. A […] Acceleron Pharma (NASDAQ:XLRN) Coverage Initiated by ... Barclays assumed coverage on shares of Acceleron Pharma (NASDAQ:XLRN) in a report published on Thursday, Benzinga reports. The firm issued an overweight rating and a $107.00 price target on the biopharmaceutical company’s stock. A number of other research analysts have also recently issued reports on the company.

XLRN Stock Price and Chart — NASDAQ:XLRN — TradingView Hi again! I've entered a partial long in XLRN at 54.88 with a target of 59.80, though I don't think it'll go quite that high. Chance of a good pullback is strong here down as far as just above the $53 mark, so not saying it's just ready to blow, lol just saying I like this one overall. XLRN Price Target - ETF Channel The median XLRN price target (a different metric than the average or mean) was $109.0 as of 2020-03-22, the highest XLRN price target in the range was $136.0 while the lowest XLRN price target in the range was $104.0, with a standard deviation of $12.865. Get the latest Zacks research report on XLRN — FREE Analysts Turn Mixed On Acceleron Pharma Inc. (NASDAQ:XLRN ... Mar 03, 2020 · The stock was given Buy rating by Citigroup in its report released on May 24, 2019, the day when the price target on the stock was placed at 66. Barclays was of a view that XLRN is Equal Weight in its latest report on May 03, 2019. Oppenheimer thinks that XLRN is worth Outperform rating.

Jan 28, 2020 · Gainers • Acceleron Pharma, Inc. (NASDAQ:XLRN) stock moved upwards by 66.3% to $87.90 during Monday's after-market session.The most recent rating by Citigroup, on January 22, is at Buy, with a

View today's stock price, news and analysis for Acceleron Pharma Inc. (XLRN). Barron's also provides information on historical stock ratings, target prices,  27 Feb 2020 02/18/20 H.C. Wainwright: Acceleron price target raised to $129 from $90 stays cautious on Gilead as remdesivir hope drives shares higher. 24 Oct 2019 She rates XLRN at Overweight (equivalent of Buy) and has a $71 price target, implying 67% upside over the next 12 months. That's one of the  28 Jan 2020 Some analysts say the compound has blockbuster potential. Acceleron's closing stock price Tuesday was $79.39, up more than 50 percent  28 Jan 2020 Piper Sandler analyst Danielle Brill reiterates an Overweight rating on Acceleron shares. 2020年1月28日 drug is sending shares of the biotech firm Acceleron Pharma soaring. One analyst more than doubled his price target on the stock, but others 

XLRN Stock Price, Forecast & News (Acceleron Pharma)

Acceleron Pharma Inc - TheStreet - Stock Market Acceleron Pharma Price Target Raised by Leerink. (XLRN) Marked As A Dead Cat Bounce Stock. By TheStreet Wire. Jul 6, 2016 10:58 AM EDT Acceleron Pharma (XLRN) Is Today's Strong On High Spotting Wide-Moat Stocks: Acceleron Pharma (XLRN), Urban ... Mar 02, 2020 · At the time the stock opened at the value of $84.32, making it a high for the given period, the value of the stock dropped by -0.74%. After the decrease, XLRN touched a low price of $82.77, calling it a day with a closing price of $86.57, which means that the price of XLRN went 85.93 below the opening price on the mentioned day. Oppenheimer Raises Acceleron Pharma (NASDAQ:XLRN) Price ...

Acceleron Pharma Inc. Stock Price (XLRN) | Barron's

1 Year % Chg 86.21. Market Cap 4.6B. Shares Outstanding 53.3M. Beta 0.90. Dividend (Yield) -. Div Amount -. Ex Div Date -. Earnings Date 2020-05-07. 1 day ago rating on Acceleron Pharma (XLRN), with a price target of $99.00. also maintained a Buy rating on the stock with a $112.00 price target. XLRN: Get the latest Acceleron Pharma stock price and detailed information including XLRN news, historical charts and realtime prices.

H.C. Wainwright analyst Edward White reiterated a Buy rating on Acceleron Pharma (XLRN – Research Report) today and set a price target of $129.00.The company’s shares closed last Monday at $93.66, close to its 52-week high of $95.95. According to TipRanks.com, White is a top 100 analyst with an average return of 28.0% and a 52.5% success rate. White covers the …

XLRN | Complete Acceleron Pharma Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Acceleron Pharma stock price target … XLRN Acceleron Pharma Inc. Common Stock - NASDAQ.com Feb 27, 2020 · Acceleron Pharma Inc. Common Stock (XLRN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. XLRN Price Target | Acceleron Pharma Stock Forecast & Ratings See Acceleron Pharma price target based on 11 analysts offering 12 month price targets for Acceleron Pharma in the last 3 months. The average price target is $109.00 with a high forecast of $138.00 and a low forecast of $72.00. The average price target represents a 27.46% increase from the last price of $85.52. Acceleron Pharma Inc. Common Stock (XLRN) Analyst Research ... Based on analysts offering 12 month price targets for XLRN in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00. Sign in to your

XLRN Stock Price and Chart — NASDAQ:XLRN — TradingView Hi again! I've entered a partial long in XLRN at 54.88 with a target of 59.80, though I don't think it'll go quite that high. Chance of a good pullback is strong here down as far as just above the $53 mark, so not saying it's just ready to blow, lol just saying I like this one overall. XLRN Price Target - ETF Channel The median XLRN price target (a different metric than the average or mean) was $109.0 as of 2020-03-22, the highest XLRN price target in the range was $136.0 while the lowest XLRN price target in the range was $104.0, with a standard deviation of $12.865. Get the latest Zacks research report on XLRN — FREE Analysts Turn Mixed On Acceleron Pharma Inc. (NASDAQ:XLRN ... Mar 03, 2020 · The stock was given Buy rating by Citigroup in its report released on May 24, 2019, the day when the price target on the stock was placed at 66. Barclays was of a view that XLRN is Equal Weight in its latest report on May 03, 2019. Oppenheimer thinks that XLRN is worth Outperform rating. Acceleron Pharma Inc. - NASDAQ:XLRN - Stock Quote & News ...